HAWK is a single-arm, phase II study that evaluated the activity of durvalumab monotherapy in 112 patients with platinum-refractory R/M HNSCC with elevated PD-L1 tumour expression (≥25%) (Table 2). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.